Ivacaftor for Chronic Obstructive Pulmonary Disease

"Applicants for this clinical trial should suffer from chronic bronchitis, and be within the 40-80 year old range. Approximately 40 individuals will receive admission to the study."

"Ivacaftor has been formulated to treat an ivacaftor-responsive cftr mutation, homozygous for f508del mutation in the cftr gene and cystic fibrosis (cf)."

"Since it's inception in 2015, Ivacaftor has been subject to multiple clinical trials. The initial research was conducted by Vertex Pharmaceuticals Incorporated and involved 1044 participants. On the back of positive Phase 3 results, there are now 21 ongoing studies being run across 23 countries and 109 cities worldwide."

"This study will assess the safety of ivacaftor by examining abnormal serum chemistry from Screening to Day 98 as its primary objective. Secondary objectives include measuring respiratory function with post-bronchodilator spirometry and assessing patient wellbeing through San Diego Shortness of Breath Questionnaire (SOBQ) and St. George Respiratory Questionnaire (SGRQ), both of which have a Minimum Clinically Important Difference (MCID) score of 5 and 4 respectively."

"According to the information hosted online at clinicaltrials.gov, this trial is actively seeking participants that meet its criteria. It was first posted on March 16th 2017 and most recently modified on March 24th 2022."

"At present, 21 medical studies are underway to assess Ivacaftor's efficacy. Of those trials, 14 occupy Phase 3 while the remainder of investigations occur at 1015 sites across Bochum and California."

"This trial includes individuals aged 40 or older, but not exceeding 80 years in age."

"Ivacaftor is believed to be relatively safe but efficacy has not been fully explored, so it scored a 2 on Power's scale of 1-3."

"Affirmative, information from clinicaltrials.gov reveals that the clinical trial is still enrolling participants. First posted on March 16th 2017 and most recently updated on March 24th 2022, this medical experiment requires 40 individuals to be recruited at a single site."